Prosecution Insights
Last updated: April 19, 2026
Application No. 17/774,571

BIOSYNTHESIS OF CHEMICALLY DIVERSIFIED NON-NATURAL TERPENE PRODUCTS

Final Rejection §102
Filed
May 05, 2022
Examiner
VAJDA, KRISTIN ANN
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
OA Round
2 (Final)
84%
Grant Probability
Favorable
3-4
OA Rounds
2y 0m
To Grant
95%
With Interview

Examiner Intelligence

Grants 84% — above average
84%
Career Allow Rate
1331 granted / 1581 resolved
+24.2% vs TC avg
Moderate +10% lift
Without
With
+10.5%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 0m
Avg Prosecution
36 currently pending
Career history
1617
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
11.2%
-28.8% vs TC avg
§102
27.6%
-12.4% vs TC avg
§112
33.6%
-6.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1581 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-26 are pending in the instant application. Claims 14-26 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to non-elected subject matter. The withdrawn subject matter is patentably distinct from the elected subject matter as it differs in structure and element and would require separate search considerations. In addition, a reference which anticipates one group would not render obvious the other. Claims 1, 2, 6-9, 12, and 13 are rejected. Claims 3-5, 10 and 11 are objected. Response to Amendment and Arguments/Remarks The amendment and arguments/remarks filed on November 14, 2025 have been fully considered and entered into the application. With regards to the 35 U.S.C. 112(b), 35 U.S.C. 112(d), 35 U.S.C. 102(a)(1) rejection as being anticipated by Nakano et al., and the claim objections, the grounds for rejection and objection are moot in view of Applicant’s amendment and the rejections and objections have been withdrawn. However, this amendment has necessitated new grounds of rejection under 35 U.S.C. 102(a)(1), which are described below. It is noted that the election of species requirement has been withdrawn (i.e., the full scope of the subject matter of claims 1-13 has been searched and examined in its entirety). New Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 2, 6-9, 12, and 13 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Johnson et al. (New Phytologist (2019) 223: 323-335). Johnson et al. discloses the compounds (Z,Z)-FPP, FPP, NPP, and GPP (see Figure 4 on page 329) which anticipate compounds of formula (I) of the claims wherein m is 0 (NPP and GPP) or 1 ((Z,Z)-FPP and FPP); the dashed lines represent a double bond; R3’-R6’ are absent; X1 is alkyl; R1 and R2 form a double bond; R1’ and R’ are methyl; R2’ is hydrogen; R3 and R5 are methyl; R4 and R6 are hydrogen; X4 is absent; and X2 is a bond. With respect to the art rejection above over claims 12 and 13, it is noted that the reference does not teach that the compounds can be used in the manner instantly claimed (i.e., enzymatically transformed into a terpenoid). However, the intended use of the claimed compounds does not patentably distinguish the compounds, per se, since such disclosed use is inherent in the reference compounds. In order to be limiting, the intended use must create a structural difference between the claimed compounds and the prior art compounds. In the instant case, the intended use does not create a structural difference, thus the intended use is not limiting. Claim Objections Claims 3-5, 10 and 11 are objected to for depending on a previous rejected claim. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KRISTIN ANN VAJDA whose telephone number is (571)270-5232. The examiner can normally be reached Mon-Fri 6:00-4:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KRISTIN A VAJDA/Primary Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

May 05, 2022
Application Filed
Jul 11, 2025
Non-Final Rejection — §102
Nov 14, 2025
Response Filed
Feb 26, 2026
Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600712
AMINO-PYRIMIDINE AMIDES
2y 5m to grant Granted Apr 14, 2026
Patent 12600745
PROCESS FOR PREPARING B-[(7a, 1713)-17-HYDROXY-7-[9-[(4,4,5,5,5-PENTAFLUOROPENTYL)SULFINYL]NONYL]ESTRA-1,3,5(10)-TRIEN-3-YL]-BORONIC ACID
2y 5m to grant Granted Apr 14, 2026
Patent 12590094
COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS
2y 5m to grant Granted Mar 31, 2026
Patent 12590111
FLAVONOID DERIVATIVE FOR TREATING DENTAL CARIES
2y 5m to grant Granted Mar 31, 2026
Patent 12590093
INDOLO[2',3':3,4]PYRIDO[2,1-B]QUINAZOLINE COMPOUND AND USE THEREOF
2y 5m to grant Granted Mar 31, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
84%
Grant Probability
95%
With Interview (+10.5%)
2y 0m
Median Time to Grant
Moderate
PTA Risk
Based on 1581 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month